GBS - GBS Inc. Stock Price, Fair Value and News

2.26USD+0.01 (+0.44%)Market Closed

Market Summary

USD2.26+0.01

Market Closed

0.44%

GBS Stock Price

View Fullscreen

GBS RSI Chart

GBS Valuation

Market Cap

7.0M

Price/Earnings (Trailing)

-0.7

Price/Sales (Trailing)

2.64

EV/EBITDA

0.14

Price/Free Cashflow

-0.98

GBS Price/Sales (Trailing)

GBS Profitability

Operating Margin

65.18%

EBT Margin

-471.58%

Return on Equity

-91.34%

Return on Assets

-58.95%

Free Cashflow Yield

-102.38%

GBS Fundamentals

GBS Revenue

Revenue (TTM)

2.7M

Rev. Growth (Yr)

80.24%

Rev. Growth (Qtr)

7.82%

GBS Earnings

Earnings (TTM)

-10.0M

Earnings Growth (Yr)

52.92%

Earnings Growth (Qtr)

-51.64%

Breaking Down GBS Revenue

Last 7 days

-2.2%

Last 30 days

-15.7%

Last 90 days

-48.7%

Trailing 12 Months

-23.4%

How does GBS drawdown profile look like?

GBS Financial Health

Current Ratio

2.02

GBS Investor Care

Shares Dilution (1Y)

79.91%

Diluted EPS (TTM)

-4.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.7M	0	0	0
2023	1.2M	1.4M	1.9M	2.3M
2022	2.0M	2.0M	748.5K	927.4K
2021	1.5M	2.0M	0	2.1M
2020	0	188.7K	636.7K	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of GBS Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 10, 2022	simeonidis harry	acquired	-	-	80,000	president
Oct 10, 2022	sakiris spiro kevin	acquired	-	-	75,000	chief financial officer
Oct 10, 2022	hurd jonathan scott	acquired	-	-	15,000	-
Oct 10, 2022	boyages steven constantine	acquired	-	-	75,000	interim ceo and chairperson
Oct 10, 2022	margelis george	acquired	-	-	15,000	-
Oct 10, 2022	fisher lawrence b	acquired	-	-	15,000	-
Oct 10, 2022	towers christopher	acquired	-	-	15,000	-
Jun 22, 2022	sakiris spiro kevin	bought	3,249	0.6498	5,000	chief financial officer
Jun 17, 2022	sakiris spiro kevin	bought	9,765	0.6115	15,970	chieffinancial officer
Feb 17, 2022	life science biosensor diagnostics pty ltd	sold	-293,774	0.51	-576,028	-

Which funds bought or sold GBS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	ADAR1 Capital Management, LLC	new	-	456,815	456,815	0.10%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-8,569	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	4,431	4,431	-%
May 15, 2024	Alyeska Investment Group, L.P.	new	-	864,180	864,180	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-9,948	-	-%
May 15, 2024	Hudson Bay Capital Management LP	new	-	456,815	456,815	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-11,519	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-52,719	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	62,633	62,633	-%
May 14, 2024	OMERS ADMINISTRATION Corp	sold off	-100	-14,327	-	-%

Are Funds Buying or Selling GBS?

Are funds buying GBS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GBS

No. of Funds

Unveiling GBS Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ionic ventures, llc	4.9%	112,803	SC 13G/A
Feb 13, 2024	lind global fund ii lp	9.9%	960,000	SC 13G/A
Feb 05, 2024	bigger capital, llc	1.7%	-	SC 13G/A
Oct 20, 2023	lind global fund ii lp	9.9%	2,450,000	SC 13G
Oct 10, 2023	lind global fund ii lp	9.9%	386,000	SC 13G
Oct 04, 2023	bigger capital fund l p	3.7%	144,500	SC 13G
Jun 01, 2023	gary w. rollins foundation	11.0%	190,489	SC 13D
Mar 13, 2023	ionic ventures, llc	9.99%	148,500	SC 13G
Mar 10, 2023	lind global fund ii lp	9.9%	148,500	SC 13G

Recent SEC filings of GBS Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 03, 2024	8-K	Current Report
Apr 18, 2024	8-K	Current Report
Apr 12, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Mar 28, 2024	424B3	Prospectus Filed
Mar 27, 2024	EFFECT	EFFECT
Mar 25, 2024	CORRESP	CORRESP
Mar 25, 2024	UPLOAD	UPLOAD

GBS Inc. News

Latest updates

GBS Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	7.8%	823,800	764,063	796,094	287,475	457,058	356,679	311,320	66,855	192,500	177,791	1,607,730	34,290	283,037	55,427	-
Cost Of Revenue	14.3%	645,311	564,815	563,763	-	424,009	112,635	-	-	-	-	-	-	-	-	-
Gross Profit	-10.4%	178,489	199,248	232,331	-	33,049	244,044	-	-	-	-	-	-	-	-	-
Operating Expenses	37.2%	3,216,066	2,343,809	2,868,567	2,791,073	6,694,128	2,644,636	1,529,692	2,154,948	1,535,329	3,644,426	-12,647,556	3,174,805	1,200,363	718,422	-
S&GA Expenses	-100.0%	-	1,705,044	2,457,060	2,432,242	1,898,754	2,245,289	1,450,418	1,462,335	1,122,004	1,003,244	1,153,223	1,013,389	671,450	521,003	-
EBITDA Margin	13.7%	-4.28	-4.97	-6.03	-8.10	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	18,561	81,664	85,076	-
Earnings Before Taxes	-	-	-	-	-	-6,352,017	-	-	-	-1,344,133	-3,463,823	-850,230	-3,142,667	-1,990,389	-1,076,915	-
EBT Margin	13.7%	-4.72	-5.47	-6.64	-8.92	-10.57	-7.65	-9.48	-3.47	-3.53	-4.23	-3.56	-	-	-	-
Net Income	-51.6%	-2,986,765	-1,969,641	-2,432,424	-2,656,028	-6,343,906	-420,600	-1,214,078	-2,073,648	-1,335,246	-3,463,823	-847,584	-3,127,813	-1,990,389	-1,076,915	-1,836,318
Net Income Margin	35.3%	-3.76	-5.82	-6.25	-7.53	-8.43	-5.44	-10.80	-4.06	-3.52	-4.22	-3.56	-	-	-	-
Free Cashflow	14.7%	-2,446,564	-2,869,158	-1,311,833	-584,338	-2,518,455	-2,380,850	-1,893,735	-1,723,205	-292,224	-1,425,567	-1,682,811	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q2
Assets	93.0%	17,039	8,827	8,700	10,355	10,669	18,048	10,160	12,352	14,359	15,236	19,107	21,859	17,453	19,966	2,476
Current Assets	291.2%	11,521	2,945	2,692	3,863	4,423	6,378	8,207	10,868	12,865	14,085	15,860	18,207	16,586	19,966	2,340
Cash Equivalents	739.8%	9,398	1,119	186	1,537	2,281	2,912	5,743	8,238	10,756	11,191	12,608	12,574	14,262	19,878	427
Inventory	-6.8%	878	942	965	980	736	671	-	-	-	-	-	-	-	-	-
Net PPE	-5.4%	560	591	665	690	478	484	416	391	-	-	-	-	-	-	-
Goodwill	-	-	-	-	-	-	4,130	3,803	-	-	-	-	-	-	-	-
Liabilities	6.5%	6,041	5,673	7,464	6,668	4,742	7,785	4,964	5,806	5,656	5,191	5,606	6,853	1,577	1,184	7,690
Current Liabilities	10.1%	5,706	5,183	6,846	5,884	3,536	4,815	2,357	4,663	4,432	4,009	2,833	3,683	1,559	1,166	7,690
Shareholder's Equity	235.3%	10,998	3,280	1,237	3,799	6,026	10,263	5,196	6,546	8,703	10,045	13,501	15,007	15,875	18,782	-
Retained Earnings	-6.4%	-49,180	-46,202	-44,232	-41,807	-39,148	-32,804	-32,384	-31,175	-29,097	-27,762	-24,302	-22,869	-22,016	-18,888	-15,832
Additional Paid-In Capital	21.9%	60,946	49,986	46,159	46,180	45,773	43,687	38,440	38,581	38,440	38,440	38,440	38,440	38,440	37,957	10,900
Shares Outstanding	97.4%	2,914	1,476	2,330	194	1,685	918	14,890	-	730	-	14,006	10,415	-	-	-
Minority Interest	-7.2%	-135	-125	-119	-111	-99.52	-91.41	-84.94	-79.15	-69.13	-60.24	-56.41	-51.23	-53.99	-39.14	-28.31
Float	-	-	-	-	-	-	3,665	-	9,857	-	17,349	-	-	-	35,140	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	14.7%	-2,446	-2,869	-1,311	-584	-2,518	-2,380	-1,893	-1,723	-292	-1,425	83.00	-1,682	-6,159	-776	-2,677	-	-	-
Share Based Compensation	-	218	-	-	-	-	260	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Investing	-	3.00	-	-	-181	174	-211	-474	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-	10,769	-	-	46.00	1,718	-	-	-	-	-	-	-	498	19,610	3,295	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GBS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)

3 Months Ended

9 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Revenue

^[1]

$ 823,800

$ 457,058

$ 2,383,957

$ 813,737

Cost of revenue (exclusive of amortization shown separately below)

^[1]

(645,311)

(424,009)

(1,773,889)

(536,644)

Gross profit

^[1]

178,489

33,049

610,068

277,093

Other income:

Government support income

^[1]

83,842

117,680

346,917

698,625

Operating expenses:

Selling, general and administrative expenses

^[1]

(2,425,830)

(1,898,754)

(6,587,934)

(5,594,461)

Development and regulatory approval expenses

^[1]

(471,313)

(299,898)

(923,712)

(380,363)

Depreciation and amortization

^[1]

(318,923)

(398,986)

(916,796)

(797,142)

Goodwill impairment

^[1]

(4,096,490)

Total operating expenses

^[1]

(3,216,066)

(6,694,128)

(8,428,442)

(10,868,456)

Loss from operations

^[1]

(2,953,735)

(6,543,399)

(7,471,457)

(9,892,738)

Other income (expense), net:

Interest expense

^[1]

(42,674)

(86,125)

(112,590)

(163,957)

Realized foreign exchange income/(loss)

^[1]

(996)

7,212

(1,551)

(8,936)

Fair value gain on revaluation of financial instrument

^[1]

269,787

175,738

2,062,878

Interest income

^[1]

10,640

508

14,288

9,587

Total other income (expense), net

^[1]

(33,030)

191,382

75,885

1,899,572

Net loss

^[1]

(2,986,765)

^[2]

(6,352,017)

^[3]

(7,395,572)

(7,993,166)

Net loss attributable to non-controlling interest

^[1]

(9,098)

(8,111)

(23,060)

(20,367)

Net loss attributable to Intelligent Bio Solutions Inc.

^[1]

(2,977,667)

(6,343,906)

(7,372,512)

(7,972,799)

Other comprehensive income/(loss), net of tax:

Foreign currency translation gain/ (loss)

^[1]

(144,026)

^[2]

(77,787)

^[3]

(86,909)

148,251

Total other comprehensive income/(loss)

^[1]

(144,026)

(77,787)

(86,909)

148,251

Comprehensive loss

^[1]

(3,130,791)

(6,429,804)

(7,482,481)

(7,844,915)

Comprehensive loss attributable to non-controlling interest

^[1]

(9,098)

(8,111)

(23,060)

(20,367)

Comprehensive loss attributable to Intelligent Bio Solutions Inc.

^[1]

$ (3,121,693)

$ (6,421,693)

$ (7,459,421)

$ (7,824,548)

Net income per common unit, basic

^[1]

$ (1.43)

$ (68.67)

$ (6.64)

$ (104.04)

Net income per common unit, diluted

^[1]

$ (1.43)

$ (68.67)

$ (6.64)

$ (104.04)

Weighted average shares outstanding, basic

^[1]

2,079,864

92,389

1,110,089

76,629

Weighted average shares outstanding, diluted

^[1]

2,079,864

92,389

1,110,089

76,629

[1]	Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.
[2]	Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.
[3]	Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.

GBS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)

Mar. 31, 2024

Jun. 30, 2023

Current assets:

Cash and cash equivalents

$ 9,397,523

$ 1,537,244

Accounts receivable, net

431,646

293,861

Inventories, net

877,905

979,907

Research and development tax incentive receivable

332,471

498,758

Other current assets

481,046

552,791

Total current assets

11,520,591

3,862,561

Property and equipment, net

559,520

690,175

Operating lease right-of-use assets

365,512

546,475

Intangibles, net

4,593,330

5,255,401

Total assets

17,038,953

10,354,612

Current liabilities:

Accounts payable and accrued expenses

2,128,747

2,610,028

Current portion of operating lease liabilities

260,377

223,447

Current portion of deferred grant income

2,288,660

2,338,057

Current employee benefit liabilities

660,010

358,942

Current portion of notes payable

368,513

353,211

Total current liabilities

5,706,307

5,883,685

Employee benefit liabilities, less current portion

30,286

24,902

Operating lease liabilities, less current portion

154,162

356,165

Notes payable, less current portion

150,426

402,862

Total liabilities

6,041,181

6,667,614

Commitments and contingencies (Note 13)

Shareholders’ equity

Common stock, $0.01 par value, 100,000,000 shares authorized, 2,913,799 and 194,200 shares issued and outstanding at March 31, 2024 and June 30, 2023, respectively

^[1]

29,135

1,942

Treasury stock, at cost, 116 shares as of March 31, 2024 and June 30, 2023, respectively

^[1]

(1)

Additional paid-in capital

60,946,174

46,180,112

Accumulated deficit

(49,180,085)

(41,807,573)

Accumulated other comprehensive loss

(662,405)

(575,496)

Total consolidated Intelligent Bio Solutions Inc. equity

11,132,818

3,798,984

Non-controlling interest

(135,046)

(111,986)

Total shareholders’ equity

10,997,772

^[2]

3,686,998

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$ 17,038,953

$ 10,354,612

[1]	Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.
[2]	Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated.

About GBS Inc.

WEBSITE	https://gbs.inc

GBS Inc. Frequently Asked Questions

What is the ticker symbol for GBS Inc.? What does GBS stand for in stocks?

GBS is the stock ticker symbol of GBS Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GBS Inc. (GBS)?

As of Fri May 17 2024, market cap of GBS Inc. is 7.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GBS stock?

You can check GBS's fair value in chart for subscribers.

What is the fair value of GBS stock?

You can check GBS's fair value in chart for subscribers. The fair value of GBS Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GBS Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GBS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GBS Inc. a good stock to buy?

The fair value guage provides a quick view whether GBS is over valued or under valued. Whether GBS Inc. is cheap or expensive depends on the assumptions which impact GBS Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GBS.

What is GBS Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, GBS's PE ratio (Price to Earnings) is -0.7 and Price to Sales (PS) ratio is 2.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GBS PE ratio will change depending on the future growth rate expectations of investors.